AUPH vs SII Comparison

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.